Trump Drops Bombshell: Wants Ozempic and Wegovy Slashed to $150 a Month
In a stunning move that shook Wall Street and Big Pharma to the core, Donald Trump announced that he wants the price of blockbuster weight-loss drugs like Ozempic and Wegovy to be just $150 a month — a massive price cut from the eye-watering $1,300 many Americans are currently paying.
This wasn’t a casual offhand comment. Trump said it loud and clear: Americans are being ripped off, and he’s coming for the pharmaceutical giants that are cashing in on one of the biggest drug booms in decades.
Within hours, pharmaceutical stocks plunged. Eli Lilly and Novo Nordisk — the two companies behind these wildly popular weight-loss drugs — saw billions wiped off their market value.
Here’s what you need to know.
These “Miracle” Weight-Loss Drugs Are Making Billions… and Costing You Even More
Drugs like Ozempic, Wegovy, and Mounjaro have taken over the weight-loss world. Originally made to treat diabetes, they’ve become the go-to solution for shedding serious pounds — and fast.
Celebrities are using them. Social media is obsessed with them. And doctors are prescribing them like candy.
But there’s a catch: these miracle shots come with a miracle-sized price tag.
In the U.S., people are paying $1,000 to $1,300 per month — and that’s if your insurance doesn’t deny coverage (which it often does). Meanwhile, in countries like the UK, the exact same drugs cost a fraction of that price.
Trump’s message? Enough is enough.
Trump: “You’re Not Paying $1,300 Anymore”
At a public event, Trump delivered the news like a mic drop.
“In London, they pay $88 for this drug. In New York, we pay $1,300. That ends now,” he said.
He promised that under his administration, Americans would pay $150 a month — just like patients in other countries. He specifically named Ozempic, calling it “the fat loss drug.”
Immediately, the financial world panicked.
Pharma Panic Mode: Stocks Crash in Real Time
The reaction was swift and brutal.
- Novo Nordisk shares tanked.
- Eli Lilly stock dropped like a rock.
- Even Hims & Hers Health, a company that offers cheaper alternatives, saw their stock plummet — because even they can’t match a $150 brand-name price.
Investors saw the writing on the wall: if Trump gets his way, Big Pharma’s fat profit margins are on the chopping block.
But Wait — Is This Actually Happening?
Right as the shockwaves hit, Dr. Mehmet Oz, now running the Centers for Medicare & Medicaid Services, stepped in with a reality check.
“We haven’t finalized anything yet,” he said. “No agreements have been made with drug companies.”
So here’s the deal: Trump has declared what he wants, but it’s not a done deal — yet.
Still, just the threat of it was enough to shake the entire pharmaceutical industry.
Why This Could Be a Game-Changer for You
If this pricing plan actually happens, it could change the lives of millions of Americans.
Right now:
- Many people can’t afford GLP-1 drugs without insurance
- Most insurance plans won’t cover them unless you have diabetes
- Even then, monthly costs can still be crushing
But at $150 a month? Suddenly, these game-changing drugs become affordable — and the obesity and diabetes epidemics could face a real turning point.
What Big Pharma Doesn’t Want You to Know
For years, drugmakers have charged Americans far more than patients in other countries — and gotten away with it.
Now, with Trump shining a spotlight on the issue, they’re in damage-control mode.
They argue high prices support innovation. They warn that slashing prices could limit future breakthroughs. But let’s be real: GLP-1 drugs have already made them billions, and they’re not exactly struggling.
This move could open the floodgates for price cuts across the entire industry — and they know it.
What Happens If Trump Gets His Way?
Here’s what could be coming if the $150 plan becomes reality:
1. Lower Drug Costs for Millions
More people could afford these drugs out-of-pocket, without insurance battles.
2. Insurance Expansion
Medicare and private insurers might finally start covering weight-loss prescriptions more broadly.
3. Pharma Reshuffle
Eli Lilly and Novo Nordisk would likely be forced to rethink their entire pricing strategy. Either they play ball — or risk losing massive market share.
4. Wall Street Watch
Investors are now on red alert. This isn’t just about weight-loss drugs. If it happens here, it could happen to any high-priced drug.
So, Will It Actually Happen?
Right now, it’s still early. No price deal is signed. No government order is in place. But the wheels are turning.
This isn’t just a political soundbite — it’s a clear warning to Big Pharma. The U.S. public is fed up, and if politicians find a way to lower prices without hurting access, voters will back it.
Keep your eyes on these next moves:
- Official government negotiations with drugmakers
- Public pressure and media coverage
- How Eli Lilly and Novo Nordisk respond
This fight is just beginning.
Final Word: Watch This Space
Trump lit the fuse — and Big Pharma just felt the blast.
If the U.S. really slashes prices on GLP-1 drugs, it could unleash a massive shakeup in the healthcare system. Cheaper access to powerful treatments. Better outcomes for patients. And a major hit to one of the most profitable sectors in the world.
Whether you love or hate Trump, this could be the most significant challenge to Big Pharma’s pricing power in years.
Buckle up. The weight-loss drug war has officially begun.
